CliffBio
biologic

Ryzneuta

efbemalenograstim alfa-vuxw

Loss of exclusivityNovember 2035projected — 12-year biologic exclusivity estimate
CompanyEvive Biotechnology Singapore PTE. LTD.

Drug detail

Brand nameRyzneuta
Active ingredientefbemalenograstim alfa-vuxw
Strength20MG/ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalNovember 2023
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.